Patient selection for IGF-I therapy.
Clayton
P E
PE
Endocrine Science Research Group, Division of Human Development, The Medical School, University of Manchester, Manchester, UK. peter.clayton@manchester.ac.uk
Ayoola
O
O
Whatmore
A J
AJ
D005260:Female; D006130:Growth Disorders / Q000188:drug therapy* / Q000235:genetics; D013006:Growth Hormone / Q000627:therapeutic use; D020249:Hormone Replacement Therapy / Q000379:methods; D006801:Humans; D018972:Insulin-Like Growth Factor Binding Protein 3 / Q000627:therapeutic use*; D007334:Insulin-Like Growth Factor I / Q000172:deficiency* / Q000235:genetics / Q000627:therapeutic use*; D008297:Male; D018579:Patient Selection
D018972:Insulin-Like Growth Factor Binding Protein 3; D007334:Insulin-Like Growth Factor I; D013006:Growth Hormone